Inozyme Pharma Stock Number Of Shares Shorted
| INZYDelisted Stock | USD 4.00 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Inozyme Pharma's long-term financial health and intrinsic value.
Inozyme |
Inozyme Pharma Company Number Of Shares Shorted Analysis
Inozyme Pharma's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Inozyme Pharma Number Of Shares Shorted | 3.38 M |
Most of Inozyme Pharma's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inozyme Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
CompetitionBased on the recorded statements, Inozyme Pharma has 3.38 M of outstending shares currently sold short by investors. This is 5.8% higher than that of the Biotechnology sector and 33.59% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 28.06% higher than that of the company.
Inozyme Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inozyme Pharma's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inozyme Pharma could also be used in its relative valuation, which is a method of valuing Inozyme Pharma by comparing valuation metrics of similar companies.Inozyme Pharma is currently under evaluation in number of shares shorted category among its peers.
Inozyme Fundamentals
| Return On Equity | -1.42 | |||
| Return On Asset | -0.48 | |||
| Current Valuation | 220.43 M | |||
| Shares Outstanding | 64.56 M | |||
| Shares Owned By Insiders | 1.26 % | |||
| Shares Owned By Institutions | 94.29 % | |||
| Number Of Shares Shorted | 3.38 M | |||
| Price To Book | 8.12 X | |||
| EBITDA | (104.03 M) | |||
| Net Income | (102.02 M) | |||
| Cash And Equivalents | 151.48 M | |||
| Cash Per Share | 3.77 X | |||
| Total Debt | 46.87 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 14.54 X | |||
| Book Value Per Share | 0.49 X | |||
| Cash Flow From Operations | (91.91 M) | |||
| Short Ratio | 0.78 X | |||
| Earnings Per Share | (1.68) X | |||
| Price To Earnings To Growth | (0.06) X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 67 | |||
| Beta | 2.29 | |||
| Market Capitalization | 258.25 M | |||
| Total Asset | 123.18 M | |||
| Retained Earnings | (387.95 M) | |||
| Working Capital | 86.78 M | |||
| Net Asset | 123.18 M |
About Inozyme Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inozyme Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inozyme Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inozyme Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Inozyme Stock
If you are still planning to invest in Inozyme Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Inozyme Pharma's history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |